TCX-201 / Tacalyx - LARVOL DELTA

TCX-201, an ADC targeting a highly specific tumor-associated carbohydrate antigen (TACA) shows excellent PK, safety profile, and preclinical efficacy in solid tumor models. (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

ADC • Preclinical • Oncology • Solid Tumor

TCX-201, a novel ADC targeting a specific tumor-associated carbohydrate antigen (TACA) with excellent preclinical efficacy, PK and safety profile in solid tumor models (AACR 2026) - "In addition to CDX models, PDX in vitro screening on PDAC and CRC models showed highly effective killing in 5/8 PDAC PDX and 2/5 CRC PDX with TCX-201 MMAE. These results, coupled with a favorable PK and safety profile make this ADC a first-in-class molecule for the treatment of various solid tumors that express different levels of the target structure.In conclusion, our antibody represents a new promising treatment option for different cancer indications and can be effectively employed as an ADC using different payloads."

ADC • Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Two novel antibodies targeting different tumor-associated carbohydrate (TACA) antigens for the treatment of solid tumors show promising preclinical activity using different modes of action (AACR 2025) - "We focus on the generation of antibodies against these specific and difficult antigens and were able to obtain two high-affinity monoclonal antibodies (mAbs), TCX-101 and TCX-201, against two distinct TACA structures that are highly expressed across a broad range of cancer indications. In vitro studies show effective killing of various pancreatic (e.g. high expressing HuP-T4 cells with an IC50 for MMAE payload of 0.3 nM) and colon cancer cell lines expressing different levels of the target (e.g. Colo-205 (high expressing) with an IC50 of 0.013 nM or LS180 (medium expressing) with an IC50 of 4.7 nM), and high efficacy for both payloads in a xenograft mouse model using HuP-T4 pancreatic cancer cells. In conclusion, our antibodies against TACAs represent new promising treatment options for different cancer indications and can be effectively employed with different modes of action, depending on the target characteristics."

Preclinical • Colon Cancer • Colorectal Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Small Cell Lung Cancer • Solid Tumor